Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections

被引:93
作者
Lestner, Jodi [1 ]
Hope, William W. [2 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Fac Med, London, England
[2] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3GE, Merseyside, England
基金
英国医学研究理事会; 美国国家卫生研究院;
关键词
antifungal; itraconazole; pharmacodynamics; pharmacokinetics; toxicodynamics; RESISTANT ASPERGILLUS-FUMIGATUS; HYDROXYPROPYL-BETA-CYCLODEXTRIN; STEADY-STATE PHARMACOKINETICS; DRUG-DRUG INTERACTION; CANDIDA-ALBICANS; DISEASES-SOCIETY; IN-VITRO; PRACTICE GUIDELINES; ORAL ITRACONAZOLE; AZOLE RESISTANCE;
D O I
10.1517/17425255.2013.794785
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Fungal infections are a major source of global morbidity and mortality. Itraconazole is a triazole antifungal agent that is widely used for the prevention and treatment of fungal infection. While newer antifungal agents are now available, itraconazole is an orally bioavailable agent with broad-spectrum antifungal activity. Itraconazole remains a useful drug for the management of allergic and invasive mycoses worldwide. Areas covered: This article provides a summary of the pharmacokinetics, pharmacodynamics and clinical uses of itraconazole. Additionally, the authors summarise the safety and recently described toxicodynamics and discuss the value of therapeutic drug monitoring (TDM) with itraconazole. The following search criteria were constructed in order to identify relevant literature using PubMed and Ovid-MEDLINE: itraconazole, triazole, pharmacokinetics, pharmacodynamics, toxicodynamics and TDM. Relevant abstracts and articles identified from reviewing secondary citations were additionally retrieved and included if relevant. Expert opinion: Itraconazole remains an important agent in the prevention and treatment of fungal infection. Itraconazole has a broad-spectrum of activity and is available in both an intravenous and oral form making long-term use in chronic mycoses practical. Itraconazole is widely used for the treatment of endemic fungal infections. Pharmacokinetic variability and clinically important drug interactions make TDM of itraconazole an important consideration.
引用
收藏
页码:911 / 926
页数:16
相关论文
共 136 条
[1]   Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-β-cyclodextrin in infants, children, and adolescents [J].
Abdel-Rahman, Susan M. ;
Jacobs, Richard F. ;
Massarella, Joseph ;
Kauffman, Ralph E. ;
Bradley, John S. ;
Kimko, Hui C. ;
Kearns, Gregory L. ;
Shalayda, Kevin ;
Curtin, Christopher ;
Maldonado, Samuel D. ;
Blumer, Jeffrey L. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (08) :2668-2673
[2]   Congestive heart failure associated with itraconazole [J].
Ahmad, SR ;
Singer, SJ ;
Leissa, BG .
LANCET, 2001, 357 (9270) :1766-1767
[3]   Pharmacodynamics of Itraconazole against Aspergillus fumigatus in an In Vitro Model of the Human Alveolus: Perspectives on the Treatment of Triazole-Resistant Infection and Utility of Airway Administration [J].
Al-Nakeeb, Zaid ;
Sudan, Ajay ;
Jeans, Adam R. ;
Gregson, Lea ;
Goodwin, Joanne ;
Warn, Peter A. ;
Felton, Timothy W. ;
Howard, Susan J. ;
Hope, William W. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (08) :4146-4153
[4]   Clinical Evidence of Interaction Between Itraconazole and Nonnucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients with Disseminated Histoplasmosis [J].
Andrade, Roberto A. ;
Evans, Richard T. ;
Hamill, Richard J. ;
Zerai, Teddy ;
Giordano, Thomas P. .
ANNALS OF PHARMACOTHERAPY, 2009, 43 (05) :908-913
[5]   EUCAST Technical Note on Aspergillus and amphotericin B, itraconazole, and posaconazole [J].
Arendrup, M. C. ;
Cuenca-Estrella, M. ;
Lass-Floel, C. ;
Hope, W. W. .
CLINICAL MICROBIOLOGY AND INFECTION, 2012, 18 (07) :E248-E250
[6]   In Vivo Emergence of Aspergillus terreus with Reduced Azole Susceptibility and a Cyp51a M217I Alteration [J].
Arendrup, Maiken C. ;
Jensen, Rasmus H. ;
Grif, Katharina ;
Skov, Marianne ;
Pressler, Tacjana ;
Johansen, Helle K. ;
Lass-Floerl, Cornelia .
JOURNAL OF INFECTIOUS DISEASES, 2012, 206 (06) :981-985
[7]   FOOD INTERACTION AND STEADY-STATE PHARMACOKINETICS OF ITRACONAZOLE CAPSULES IN HEALTHY MALE-VOLUNTEERS [J].
BARONE, JA ;
KOH, JG ;
BIERMAN, RH ;
COLAIZZI, JL ;
SWANSON, KA ;
GAFFAR, MC ;
MOSKOVITZ, BL ;
MECHLINSKI, W ;
VANDEVELDE, V .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (04) :778-784
[8]  
Barone JA, 1998, PHARMACOTHERAPY, V18, P295
[9]   Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers [J].
Barone, JA ;
Moskovitz, BL ;
Guarnieri, J ;
Hassell, AE ;
Colaizzi, JL ;
Bierman, RH ;
Jessen, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (07) :1862-1865
[10]   Peripheral neuropathy in patients on long-term triazole antifungal therapy [J].
Baxter, Caroline G. ;
Marshall, Andrew ;
Roberts, Mark ;
Felton, Timothy W. ;
Denning, David W. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (09) :2136-2139